Skip to content
Sectors How it works Pricing Client stories

Insights

Companies Live signals Events Markets Trends Company lists
Log in
Platform Signal Tracker API Radar Book a 7-day Readout
Vuja De Sciences logo — Vuja De is dedicated to developing cancer metastasis treatme...

Vuja De Sciences

Vuja De is dedicated to developing cancer metastasis treatments that prevent cancer progression and recurrence.

Founded 2017 7 employees Venture round Biotechnology, Health Care +2

General Information

Company Name Vuja De Sciences
Founded Year 2017
Founders / Decision Makers
Team member
Employees 7
Industries Biotechnology, Health Care, Health and Wellness +1
Funding Stage Venture round
Social

BounceWatch is an independent company data service, not affiliated with Vuja De Sciences. To contact Vuja De Sciences, visit vujade-life.com.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

How does Vuja De Sciences compare?

A PDF of Vuja De Sciences and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.

See a sample report

This takes a few seconds: we look beyond our own index too.

Meeting Vuja De Sciences soon?

A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample

About Vuja De Sciences

Vuja De Sciences is a biotechnology startup that is focused on developing treatments for cancer metastasis, with the aim of preventing cancer progression and recurrence. The company's initial focus is on osteosarcoma, a rare bone cancer that predominantly affects adolescents, before expanding to other types of cancer. Vuja De Sciences employs advanced laboratory technologies for metastatic preclinical endpoints in combination with Comparative Oncology to minimize risk and optimize product development for successful human oncology clinical trials. The company is currently testing both repurposed drugs previously used in human clinical trials and novel preclinical drugs. In Comparative Oncology, canine patients with naturally occurring cancer are included in clinical trials, offering potential benefits for both humans and their furry companions. Importantly, dog osteosarcoma closely mirrors human osteosarcoma, making drugs effective in dogs highly relevant to human treatment. Additionally, the faster cancer progression in dogs is advantageous for cancer recurrence trials, as it allows for the acceleration of processes that may take years in humans. Founded in 2017, Vuja De Sciences operates in the industries of biotechnology, healthcare, health and wellness, and life sciences. The company received its most recent investment, a Venture - Series Unknown round, on 28 May 2024. The specific investors involved in this funding round have not been disclosed.

Business keywords: Cancer Metastasis Treatments, Preventing Cancer Progression, Recurrence Prevention, Osteosarcoma Treatment, Comparative Oncology, Metastatic Preclinical Endpoints, Drug Repurposing, Novel Preclinical Drugs, Canine Clinical Trials, Maintenance Therapy, Adjuvant Therapy, Phenotypic Screening, Pediatric Cancer, Drug Screening

Funding Rounds & Investors (4)

View All
Funding Stage Amount Investors Lead Investors Date
Venture Series Unknown Undisclosed -
28 May 2024
Venture Series Unknown Undisclosed -
30 Oct 2023
Venture Series Unknown Undisclosed -
29 Nov 2022
Debt Financing Undisclosed -
24 Apr 2019

Vuja De Sciences Alternatives & Competitors

View All Alternatives
Vuja De Sciences vs
Acomhal Research, Inc.
Acomhal Research, Inc. United States

Providing novel and effective therapeutic approaches to prevent tumor recurrence and metastasis

Grant
2 employees
Biotechnology, Health Care
Vuja De Sciences vs
Galera Therapeutics, Inc.
Galera Therapeutics, Inc. United States

Transforming the science and treatment of cancer

IPO
11 employees
Biotechnology, Health and Wellness
Vuja De Sciences vs
Inspirna, Inc.
Inspirna, Inc. United States

Converting cancer to a manageable, chronic condition

Series D
12 employees
Biotechnology, Health Care
View all alternatives

FAQ About Vuja De Sciences

Vuja De is dedicated to developing cancer metastasis treatments that prevent cancer progression and recurrence.
Vuja De Sciences was founded in 2017.
Vuja De Sciences operates in Biotechnology, Health Care, Health and Wellness and Life Sciences. Its work centres on Cancer Metastasis Treatments, Preventing Cancer Progression, Recurrence Prevention and Osteosarcoma Treatment.
Vuja De Sciences has approximately 7 employees.
Vuja De Sciences has completed 4 funding rounds. The latest funding stage is Venture round.
Top alternatives and competitors to Vuja De Sciences include Acomhal Research, Inc., Galera Therapeutics, Inc., Inspirna, Inc., Oncorena AB, Sopherion Therapeutics. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
Vuja De Sciences and Acomhal Research, Inc. are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for Vuja De Sciences, https://bouncewatch.com/company/vuja-de-sciences, updated 3 December 2024. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Talk to an analyst Book a 7-day Readout